Successful anticoagulation with hirudin in a patient with mesenteric venous thrombosis and multiple coagulation abnormalities

Vascular Medicine

Volumn 5, Issue 3, 2000, Pages 159-162

  Gordon, M B ^a   Beckman, J A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Deep vein thrombosis; Hirudin; Polycythemia vera; Protein C deficiency; Thrombosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; HIRUDIN; PROTEIN C; PROTEIN S;

ADULT; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; INFARCTION; MESENTERIC VEIN THROMBOSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY;

EID: 0033769598     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x0000500305     Document Type: Article

References (30)

1. Mesenteric venous thrombosis and antithrombin III deficiency
2. Occlusive mesenteric infarction. A retrospective study of 83 cases
3. Mesenteric infarction
4. Mesenteric venous thrombosis: Still a lethal disease in the 1990's
5. Mesenteric venous thrombosis
6. Mesenteric venous thrombosis: 1911-1984
7. Chronic mesenteric venous thrombosis: Difficult diagnosis and therapy
8. Two-dimensional MR angiography in the evaluation of abdominal veins with gradient refocused sequences
9. Acute mesenteric venous thrombosis. Revisited in a time of diagnostic clarity
10. Thrombophilia as a multigenic disorder
11. Prevalence of protein C deficiency in the healthy population
12. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
13. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis
14. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden
15. Low protein S in essential thrombocythemia with thrombosis
16. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families
17. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
18. Frequency of venous thrombosis after myocardial infarction
19. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke
20. Effects of low-dose subcutaneous heparin on the occurrence of deep vein thrombosis in patients with ischemic stroke
21. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-venous thrombosis after myocardial infarction
22. Antithrombotic agents and thromboembolic disease
23. Antibodies from patients with heparin-induced-thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
24. Heparin
25. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery
26. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
27. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
28. Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin
29. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
30. The Pharmacology of antithrombotic and antiplatelet agents